ADC Therapeutics SA Altman Z-Score
ADCT|Modified Z-Score (book value) based on FY2025 data
ADC Therapeutics SA's Altman Z-Score of -4.83 places the company in the "distress zone" (below 1.23). Companies in this range have historically shown higher rates of financial distress (FY2025).
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -4.83 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Distress Zone (< 1.23)
Distress zone - elevated risk of financial difficulties
The Altman Z-Score predicts bankruptcy risk using 5 financial ratios. Learn more
Components: book value of equity, working capital, retained earnings, EBIT, and revenue-to-assets — all derived from SEC FY2025 10-K filings.
5-Factor Decomposition
| Component | Ratio | Weight | Contribution |
|---|---|---|---|
| Working Capital / Total Assets | 0.731 | 0.717 | 0.524 |
| Retained Earnings / Total Assets | -5.062 | 0.847 | -4.288 |
| EBIT / Total Assets | -0.376 | 3.107 | -1.168 |
| Book Equity / Total Liabilities | -0.365 | 0.420 | -0.153 |
| Revenue / Total Assets | 0.252 | 0.998 | 0.251 |
| Total Z-Score | -4.83 | ||
As of FY2025 · SEC 10-K · Updated Jun 24, 2026
Z-Score Zones
Safe Zone - Company is in strong financial health with low bankruptcy risk.
Grey Zone - Uncertain financial position. Requires closer monitoring.
Distress Zone - Elevated probability of financial difficulties.